Hematological immune related adverse events after treatment with immune checkpoint inhibitors
With the increasing use of checkpoint inhibitors, rare immune-related adverse events (irAE) are being identified. Haematological irAE (hem-irAE) are difficult to treat and have shown high mortality rates. In order to improve side-effect management for these potentially life-threatening events, we analysed frequency, severity and outcomes.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Rafaela Kramer, Anne Zaremba, Alvaro Moreira, Selma Ugurel, Douglas B. Johnson, Jessica C. Hassel, Martin Salzmann, Anja Gesierich, Alison Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pf öhler, Adriana Hepner, Georgina V. Long, Alexander Tags: Original Research Source Type: research